157 related articles for article (PubMed ID: 28506734)
1. mTOR, VEGF, PDGFR, and c-kit signaling pathway activation in Kaposi sarcoma.
Kerr DA; Busarla SVP; Gimbel DC; Sohani AR; Nazarian RM
Hum Pathol; 2017 Jul; 65():157-165. PubMed ID: 28506734
[TBL] [Abstract][Full Text] [Related]
2. Role of HHV-8 and mTOR pathway in post-transplant Kaposi sarcoma staging.
Hernández-Sierra A; Rovira J; Petit A; Moya-Rull D; Mazuecos MA; Sánchez-Fructuoso AI; Errasti P; Idoate MÁ; Cruzado JM; Vidal A; Diekmann F; Oppenheimer F; Campistol JM; Revuelta I
Transpl Int; 2016 Sep; 29(9):1008-16. PubMed ID: 27208691
[TBL] [Abstract][Full Text] [Related]
3. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
4. A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.
Uldrick TS; Gonçalves PH; Wyvill KM; Peer CJ; Bernstein W; Aleman K; Polizzotto MN; Venzon D; Steinberg SM; Marshall V; Whitby D; Little RF; Wright JJ; Rudek MA; Figg WD; Yarchoan R
Oncologist; 2017 May; 22(5):505-e49. PubMed ID: 28341759
[TBL] [Abstract][Full Text] [Related]
5. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy.
Iwenofu OH; Lackman RD; Staddon AP; Goodwin DG; Haupt HM; Brooks JS
Mod Pathol; 2008 Mar; 21(3):231-7. PubMed ID: 18157089
[TBL] [Abstract][Full Text] [Related]
6. C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma.
Pantanowitz L; Schwartz EJ; Dezube BJ; Kohler S; Dorfman RF; Tahan SR
Appl Immunohistochem Mol Morphol; 2005 Jun; 13(2):162-6. PubMed ID: 15894929
[TBL] [Abstract][Full Text] [Related]
7. Alteration of PDGFRβ-Akt-mTOR pathway signaling in fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Hiraki-Hotokebuchi Y; Yamada Y; Kohashi K; Yamamoto H; Endo M; Setsu N; Yuki K; Ito T; Iwamoto Y; Furue M; Oda Y
Hum Pathol; 2017 Sep; 67():60-68. PubMed ID: 28711648
[TBL] [Abstract][Full Text] [Related]
8. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer.
Trinh XB; Tjalma WA; Vermeulen PB; Van den Eynden G; Van der Auwera I; Van Laere SJ; Helleman J; Berns EM; Dirix LY; van Dam PA
Br J Cancer; 2009 Mar; 100(6):971-8. PubMed ID: 19240722
[TBL] [Abstract][Full Text] [Related]
9. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract][Full Text] [Related]
11. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
12. Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Baek MH; Park JY; Rhim CC; Kim JH; Park Y; Kim KR; Nam JH
Gynecol Obstet Invest; 2017; 82(4):329-339. PubMed ID: 28125812
[TBL] [Abstract][Full Text] [Related]
13. Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene.
Martin D; Nguyen Q; Molinolo A; Gutkind JS
Oncogene; 2014 May; 33(18):2405-12. PubMed ID: 23708663
[TBL] [Abstract][Full Text] [Related]
14. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies.
Youssef NS; Said AM
Int J Clin Exp Pathol; 2014; 7(9):5725-37. PubMed ID: 25337214
[TBL] [Abstract][Full Text] [Related]
16. Response to sunitinib malate in advanced alveolar soft part sarcoma.
Stacchiotti S; Tamborini E; Marrari A; Brich S; Rota SA; Orsenigo M; Crippa F; Morosi C; Gronchi A; Pierotti MA; Casali PG; Pilotti S
Clin Cancer Res; 2009 Feb; 15(3):1096-104. PubMed ID: 19188185
[TBL] [Abstract][Full Text] [Related]
17. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
18. Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
Chaisuparat R; Hu J; Jham BC; Knight ZA; Shokat KM; Montaner S
Cancer Res; 2008 Oct; 68(20):8361-8. PubMed ID: 18922908
[TBL] [Abstract][Full Text] [Related]
19. c-Kit (CD117) expression in classic Kaposi's sarcoma.
Kandemir NO; Gun BD; Bahadir B; Yurdakan G; Ozdemir N; Karadayi N; Ozdamar SO
Clin Exp Dermatol; 2010 Jul; 35(5):525-30. PubMed ID: 19874361
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma.
Potti A; Moazzam N; Langness E; Sholes K; Tendulkar K; Koch M; Kargas S
J Cancer Res Clin Oncol; 2004 Feb; 130(2):80-6. PubMed ID: 14634801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
